piracetam / Generic mfg. - LARVOL DELTA

A minimal three-arm oral regimen for healthspan: mechanistic alignment with transcriptomic signals from a large parental-lifespan GWAS. (PubMed, Front Aging) - "Building on those directional findings, this short communication proposes a minimal three-arm oral regimen with unequal evidentiary weight: first, the Cheung Glutamatergic Regimen, consisting of low-dose dextromethorphan potentiated by a CYP2D6 inhibitor together with piracetam and L-glutamine, as an exploratory adjunct aimed at preserving residual functional connectivity; second, daily nicotinamide mononucleotide and N-acetylcysteine with pulsed senolytics for NAD + salvage and senescence modulation; and third, GLP-1 receptor agonism for metabolic reprogramming. The regimen is fully oral, uses conservative dosing, and draws on prior therapeutic or human-exposure data, although the proposed combination has no established safety profile. Although direct combination data are lacking and the foundational TWAS remains a preprint, the components show plausible but uneven mechanistic alignment with the TWAS signals and may justify carefully designed, safety-focused pilot..."

Journal

A Staged Translational Framework for Evaluating Oral Glutamatergic and Senescence-Modulating Strategies in Treatment-Resistant Depression. (PubMed, Drug Des Devel Ther) - "The central hypothesis is that an oral dextromethorphan-CYP2D6-inhibitor-piracetam regimen could, if pharmacokinetically and clinically validated, initiate glutamatergic plasticity, whereas nicotinamide mononucleotide (NMN) plus N-acetylcysteine (NAC), followed only at a later stage by a candidate senescence-directed agent, could be evaluated for effects on the redox, bioenergetic, inflammatory, and cellular-aging context associated with response durability in a biomarker-enriched subset of unipolar TRD...Dasatinib plus quercetin is therefore positioned as a later-stage, specialist-supervised research probe rather than a routine psychiatric augmentation. No clinical role can yet be assigned to any proposed combination, and none should be used outside formal research protocols. The proposed development sequence prioritizes pharmacokinetic characterization, safety, target engagement, biomarker-defined subgroup selection, controlled efficacy testing, and independent..."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Predictors of Psychoactive and Nootropic Substance Use Among Romanian University Healthcare Students: The Interplay Between Academic Anxiety and Educational Advancement. (PubMed, Healthcare (Basel)) - "It has been demonstrated that the probability of using synthetic nootropics (piracetam/cerebrolysin) increases by 1.86 times (OR = 1.86, p = 0.021) as university education progresses (nN= 335). The findings of this study highlight that many university students in the healthcare field use cognitive stimulants during periods of intellectual overload, with more than 40% of participants utilizing CEs daily or weekly in periods of academic stress. Overload schedule, academic stress, the knowledge about their positive effects, and psychosocial contexts influence consumption."

Journal • Cardiovascular • Fatigue • Mood Disorders • Psychiatry

Different Treatment Options Used for Post Covid-19 Syndrome (clinicaltrials.gov) - P=N/A | N=90 | Completed | Sponsor: Beni-Suef University

New trial • Infectious Disease • Novel Coronavirus Disease

Effect of Ginkgo Biloba Leaves Combined with Piracetam on Cognitive Function and Serum Inflammatory Factor Levels in Patients with Acute Ischemic Stroke (ChiCTR) - P=N/A | N=988 | Completed | Sponsor: Chongqing Yubei District Traditional Chinese Medicine Hospital; Chongqing Yubei District Traditional Chinese Medicine Hospital

New trial • Cardiovascular • Ischemic stroke

Differential Improvement in Obsessive Rumination and Fantasy Intrusions Versus Attachment-Related Emotional Dysregulation During Oral Glutamatergic Augmentation in a 16-Year-Old Adolescent. (PubMed, Cureus) - "A low-to-moderate-intensity Cheung glutamatergic regimen-like strategy was introduced, consisting of dextromethorphan, a CYP2D6-inhibiting antidepressant, and piracetam, with risperidone co-prescribed for fantasy-related cognitions, overvalued ideas, and obsessive instability. However, interpretation is limited by polypharmacy, risperidone titration, selective serotonin reuptake inhibitor (SSRI) effects, supportive care, natural symptom fluctuation, and the absence of formal obsessive-compulsive ratings or withdrawal/rechallenge. This case is best viewed as hypothesis-generating."

Journal • Anorexia • CNS Disorders • Depression • General Anxiety Disorder • Mood Disorders • Psychiatry • Sleep Disorder

Lantana camara L. (Verbenaceae) attenuates Ischemia-induced olfactory dysfunction by targeting the α7 nAChR allosteric site and mitigating oxidative-inflammatory cascades in the rat olfactory-memory axis. (PubMed, IBRO Neurosci Rep) - "Animals were treated with AELC (140, 280, and 560 mg/kg), minocycline (100 mg/kg), or piracetam (250 mg/kg) as reference compounds. Kigelinone exhibited predicted binding interactions at a site topographically consistent with known allosteric modulators of α7 nAChR, forming a hydrogen bond with Ala262 of the M2 transmembrane helix, a mechanistic hypothesis warranting functional validation. These findings establish a reliable rat model of post-stroke olfactory dysfunction and demonstrate that L. camara confers significant neuroprotection by modulating the cholinergic-antioxidant-neuroinflammatory axis, validating its ethnomedicinal use and offering a promising natural scaffold for the development of targeted therapeutics against ischemic brain injury."

Journal • Preclinical • Cardiovascular • CNS Disorders • Cognitive Disorders • Inflammation • Ischemic stroke • Reperfusion Injury • Vascular Neurology • IL1B • TNFA

Optimized Oral Glutamatergic Augmentation in Refractory Home-Dominant Contamination Obsessive-Compulsive Disorder With Somatic, Affective, and Motivational Features: A Case Report of Incremental Functional Gains. (PubMed, Cureus) - "The Cheung glutamatergic regimen has been proposed as an oral, low-cost, ketamine-informed glutamatergic strategy using dextromethorphan, CYP2D6 inhibition, piracetam, and L-glutamine to modulate glutamatergic plasticity...A glutamatergic-oriented augmentation strategy was used as part of a complex, evolving regimen built around dextromethorphan, piracetam, and later L-glutamine, with pharmacokinetic potentiation via CYP2D6-inhibiting antidepressants, including fluoxetine, bupropion, and later low-dose paroxetine. Low-dose risperidone, clomipramine, pregabalin, propranolol, cyproheptadine, and other symptom-focused adjuncts were used and adjusted according to response and tolerability...The response was incomplete but clinically meaningful, especially in affective, somatic, motivational, and functional domains. Larger controlled studies are needed, and home-targeted exposure-based work remains essential."

Journal • CNS Disorders • Fatigue • General Anxiety Disorder • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Suicidal Ideation

Shrimp Oil Enhances Cognition by Suppressing Neuroinflammation in a Chronic Cerebral Hypoperfusion Rat Model. (PubMed, Mol Nutr Food Res) - "Male Wistar rats subjected to bilateral common carotid artery occlusion received oral shrimp oil or piracetam once daily for 5 weeks...Inflammation was more likely suppressed by upregulated AMPK and sirtuin-1 (SIRT1) pathway, but not related to PPARγ signaling. These findings suggest that shrimp oil is a promising candidate for the treatment of VaD."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Inflammation • Solid Tumor • MBP • NLRP3 • PPARG • TLR4

Case Report: Oral glutamatergic augmentation for trauma-related disorders with fluoxetine-/bupropion-potentiated dextromethorphan ± piracetam: a four-patient case series. (PubMed, Front Psychiatry) - "Traditional monoaminergic medications often offer limited relief for the physical and cognitive symptoms of post-traumatic stress disorder (PTSD) and complex PTSD. These findings are strictly hypothesis-generating and broaden the ketamine/Auvelity framework to trauma-spectrum presentations. They suggest that further controlled investigation into oral NMDA-AMPA modulators may be warranted for trauma-related conditions."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Hypertension • Mood Disorders • Pain • Post-traumatic Stress Disorder • Psychiatry

Longitudinal Outcomes of Oral Glutamatergic Augmentation in Trauma-Related Dissociation: A Six-Month Case Study. (PubMed, Cureus) - "Over approximately seven months of documented outpatient psychiatric follow-up from 14 October 2025 to 4 May 2026, she was treated in an outpatient setting with an oral regimen consisting of dextromethorphan 30-60 mg/day, fluoxetine 10 mg/day, piracetam 600-1200 mg/day, and low-dose antipsychotic medication, with later medication adjustments according to tolerability and clinical response. This case suggests that oral NMDA-AMPA modulation may support progressive recovery of cognitive integration and functional capacity in trauma-related dissociation, while residual anxiety and interpersonal reactivity may require additional psychotherapeutic or targeted approaches. The case adds hypothesis-generating longitudinal support for low-cost glutamatergic augmentation in routine outpatient practice."

Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Neuroprotective effects of piracetam in vascular dementia: a review of toll-like receptor 4 -mediated neuroinflammatory pathways. (PubMed, Inflammopharmacology) - "In particular, studies reporting the suppression of TLR4-mediated neuroinflammatory responses by piracetam are discussed, along with emerging evidence that piracetam may also modulate signaling cascades that converge on TLR4-associated inflammatory networks. Finally, the limitations of the current evidence are addressed, and further research directions are proposed to determine whether modulation of TLR4-centered inflammatory pathways by pleiotropic agents such as piracetam can provide clinically meaningful benefits in vascular cognitive impairment."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Developmental Disorders • Inflammation • TLR4

Longitudinal Management of Post-traumatic Brain Injury Bipolar-Spectrum Disorder With Low-Dose Oral Glutamatergic Augmentation: Extended Follow-Up Revealing Induction, Overshoot, Stabilization, and Transition to PRN Maintenance. (PubMed, Cureus) - "After partial improvement on valproate, risperidone, and Deanxit, dextromethorphan 30 mg nightly and piracetam 600 mg nightly were added on 5 November 2025...Later medications included aripiprazole, paroxetine-controlled release, pregabalin, and low-dose quetiapine...The case is also only hypothesis-generating in relation to transcriptomic findings implicating bipolar-specific plasticity-related biology. Low-dose oral glutamatergic augmentation may warrant study as a closely monitored induction and consolidation strategy in post-TBI bipolar-spectrum illness, but prospective controlled trials are needed before broader recommendations can be made."

Journal • Bipolar Disorder • CNS Disorders • General Anxiety Disorder • Insomnia • Psychiatry • Sleep Disorder • Vascular Neurology

Inhibitor-Free Variant of the Cheung Regimen: Successful Adjunctive Therapy in Long-Standing Hypochondriasis With Prominent Somatic Features. (PubMed, Cureus) - "Interest has shifted toward glutamatergic agents that mimic ketamine's rapid synaptic effects...Escitalopram, later switched to fluoxetine, plus intermittent low-dose atypical antipsychotics and benzodiazepines, produced only partial relief...Even without CYP2D6 inhibition, the pairing of low-dose dextromethorphan (N-methyl-D-aspartate antagonism) and piracetam (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid potentiation) may trigger enough neuroplastic change to quiet refractory hypochondriacal OCD. Although confounded by ongoing medications, recent changes to the background regimen, and the absence of CYP2D6 genotyping or structured OCD ratings, this single observation encourages further controlled study of low-risk glutamatergic augmentation for anxiety-spectrum disorders that defy conventional care."

Journal • CNS Disorders • Heart Failure • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Sleep Disorder

A Developmental Taxonomy of Autism and the Precision Timing of the Cheung Glutamatergic Regimen. (PubMed, Cureus) - "Against this backdrop, the Cheung glutamatergic regimen--a low-cost, orally available combination of dextromethorphan, a CYP2D6-inhibiting antidepressant, piracetam, and L-glutamine--is proposed as a ketamine-mimetic plasticity agent. This refined, subtype- and timing-specific framework carries important clinical implications and underscores the urgent need for biomarker-stratified randomised trials using synaptic density imaging and circuit-level outcomes. Keywords: autism heterogeneity, synaptic pruning, LRRK2, transcriptome-wide association study, glutamatergic enhancement, precision medicine."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Psychiatry • LRRK2

Integrative genomic analysis identifies key target genes and candidate drugs for spinal stenosis. (PubMed, Front Mol Neurosci) - "Molecular docking identified six high-affinity compounds: Balsalazide and Eltrombopag for KAT5, Magnesium Citrate and Ferric Citrate for TET2, and Piracetam and Deferiprone for TAF10. These findings elucidate novel genetic and cellular mechanisms underlying spinal stenosis, highlighting the role of TGF-β pathway in disease progression. The identified compounds offer promising therapeutic interventions, bridging genomic discoveries to clinical applications and paving the way for targeted treatment strategies."

Journal • Fibrosis • Immunology • Musculoskeletal Diseases • Orthopedics • TET2 • TGFB1

The Cheung Glutamatergic Regimen as a candidate for primary and secondary prevention of Alzheimer's disease onset. (PubMed, J Alzheimers Dis Rep) - "Here we advance a testable hypothesis: an all-oral "synaptogenic stack" could mimic ketamine's downstream benefits-namely, the rise in brain-derived neurotrophic factor and the activation of mechanistic target of rapamycin (mTOR)-while avoiding its toxicities...First, dextromethorphan, kept in circulation with a small dose of a CYP2D6 inhibitor, provides gentle NMDA antagonism. Second, piracetam acts as a positive modulator of AMPA receptors, boosting fast excitatory transmission...If this mechanism proves sound, the regimen offers a low-cost, scalable way to delay the clinical onset of AD, particularly in people who already show prodromal biomarkers or genetic risk. Prospective trials are needed to evaluate safety, target engagement, and long-term cognitive outcomes."

Journal • Alzheimer's Disease • CNS Disorders • BDNF • mTOR

DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs. (PubMed, Front Psychiatry) - "Intravenous ketamine achieves this flip but is hampered by dissociation and logistics, while dextromethorphan + bupropion (Auvelity®) primarily supplies the initial NMDA blockade and yields slower, less durable benefit. We hypothesize that a fully oral, low-cost, four-component regimen may be able to approximate ketamine's full plasticity cascade (1) dextromethorphan (DXM) for NMDA antagonism; (2) a potent CYP2D6 inhibitor (fluoxetine, paroxetine, or high-dose duloxetine) to prolong DXM exposure; (3) piracetam as an AMPA positive allosteric modulator; and (4) micronized L-glutamine to restore presynaptic glutamate pools and buffer against excitotoxicity. Preclinical evidence supports mechanistic synergy along the same axis, but the full combination remains untested in humans. This hypothesis warrants formal preclinical and clinical evaluation."

Journal • CNS Disorders • Depression • Psychiatry

Solid lipid nanoparticles enhance piracetam's neuroprotective action in streptozotocin-induced cognitive dysfunction. (PubMed, Discov Nano) - "Key brain pharmacokinetic parameters like AUC, AUMC, MRT etc. were substantially improved for PSLNs than plain piracetam, signifying higher accumulation and retention of the drug following nanoencapsulation. However, futuristic studies are necessary to establish PSLNs as a potent modality against diabetes-induced cognitive dysfunction in clinical settings."

Journal • Cognitive Disorders • Diabetes • Metabolic Disorders

Effects of Gelatin Hydrolysate from Bigeye Snapper (Priacanthus tayenus) Skin in Mitigating Oxidative Stress in Chronic Cerebral Hypoperfusion Rats. (PubMed, Int J Mol Sci) - "Male Wistar rats underwent bilateral common carotid artery occlusion to induce CCH and were randomly divided into five groups: (1) sham, (2) 2-vessel occlusion (2VO), (3) 2VO + 250 mg/kg GH, (4) 2VO + 500 mg/kg GH, and (5) 2VO + piracetam...Additionally, GH treatment ameliorated Tau protein hyperphosphorylation and improved synaptic function. Overall, GH exerted neuroprotective effects against oxidative stress-related neuronal damage and enhanced neuroplasticity, learning, and memory in rats with CCH-induced cognitive impairment."

IO biomarker • Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Vascular Neurology • BCL2 • CASP3 • NOX4

Repurposing of piracetam to alleviate doxorubicin-induced cardiotoxicity in rats: Targeting TLR2/MyD88/AP-1/NF-κB and VEGF/eNOS signaling pathways. (PubMed, Toxicol Mech Methods) - "Interestingly, findings detected reducing the cardioprotective impact of PIRA on concurrent pretreatment with L-NAME, indicating the crucial role of eNOS in modulating this protection. This study revealed that PIRA ameliorated the DOXO-evoked cardiotoxicity via modulation of TLR2/MyD88/AP-1/NF-κB as well as VEGF/eNOS signaling cascades."

IO biomarker • Journal • Preclinical • Cardiovascular • Oncology • CASP3 • MYD88 • NOS3 • TLR2

Evaluation of Neuropsychiatric Events in Patients Receiving Levetiracetam for Seizure Prophylaxis Following Traumatic Brain Injury. (PubMed, J Pharm Technol) - "Background: Levetiracetam is a soluble ethyl analogue of the nootropic agent piracetam that is utilized primarily for epilepsy treatment. Studies have shown levetiracetam has preferred pharmacokinetic and pharmacodynamic properties compared to phenytoin, however, limited data exist regarding neuropsychiatric side effects...There were 14 patients (25.5%) with a history of psychiatric disorders, and just 1 of those patients experienced a neuropsychiatric event while receiving levetiracetam. Levetiracetam is a well-tolerated antiepileptic agent for patients requiring seizure prophylaxis post TBI and did not demonstrate a significant incidence of neuropsychiatric events in this evaluation."

Journal • CNS Disorders • Critical care • Epilepsy • Mental Retardation • Psychiatry • Vascular Neurology

Pharmacokinetics and Bioequivalence Evaluation of Piracetam Tablet: A Randomized, Single-Dose, Two-Period, Crossover Study in Healthy Chinese Participants Under Fasting and Fed Conditions. (PubMed, Drugs R D) - "The test piracetam tablet was demonstrated to be bioequivalent to the reference formulation with respect to the rate and extent of absorption under both fasting and fed conditions in healthy Chinese participants. The comparable safety and tolerability profiles support the clinical interchangeability of the generic and reference piracetam formulations."

Journal • PK/PD data • Alzheimer's Disease • Cognitive Disorders

Neuropsychiatric Events With Levetiracetam for Seizure Prophylaxis Following Traumatic Brain Injury (SCCM 2026) - "Introduction: Levetiracetam (LEV) is a soluble ethyl analogue of the nootropic agent piracetam that is utilized primarily for epilepsy treatment. Levetiracetam is a well-tolerated antiepileptic agent for patients requiring seizure prophylaxis post-TBI. This study did not reveal a significant amount of neuropsychiatric effects associated with LEV, however; additional research is needed to quantify the incidence of this known adverse effect with other risk factors and confounding variables."

CNS Disorders • Epilepsy • Mental Retardation • Psychiatry • Vascular Neurology

Marked Improvement in Treatment-Intolerant Obsessive-Compulsive Disorder in an Adolescent Using a Glutamatergic Regimen With Dextromethorphan, Piracetam, and Goldenseal Root. (PubMed, Cureus) - "A 16-year-old boy with severe obsessive-compulsive disorder (OCD), characterized by health-focused obsessions, intrusive ruminations, derealization, and significant functional impairment, failed to tolerate standard serotonergic agents (escitalopram, fluoxetine) and bupropion due to worsening anxiety, somatic concerns, or headaches. An oral glutamatergic regimen was initiated with dextromethorphan 30 mg/day for N-methyl-D-aspartate (NMDA) antagonism, piracetam 1,200 mg/day for AMPA modulation, and goldenseal (Hydrastis canadensis) root extract 600 mg/day as a botanical CYP2D6 inhibitor to prolong dextromethorphan exposure, alongside low-dose pregabalin, risperidone, and aripiprazole for ancillary support...These benefits lasted for two months, and there were no negative effects from goldenseal. This case indicates that a cost-effective, entirely oral amalgamation of a prevalent cough suppressant, a nootropic, and a botanical supplement may yield ketamine-like..."

Journal • CNS Disorders • Cough • Mood Disorders • Obsessive-Compulsive Disorder • Pain • Psychiatry • Respiratory Diseases